Grindeks AS (Grindeks JSC) is a Latvia-based joint stock company engaged in the pharmaceutical sector. The Company is engaged in the production of pharmaceutical and medical products, and phytochemical medicine. The Company offers products, such as: ointments, cough and cold medications, anti-inflammatory agents, gastroenterological agents, tonics and natural health products, as well as active pharmaceutical substances. The Company’s research activities are mainly focused towards the development of cardiovascular medications, neurological medications, anti cancer agents and antiviral drugs. The Company is active domestically and abroad, mainly in the Commonwealth of Independent State countries. It also owns four subsidiaries, Tallin Pharmaceutical Plant JSC, Namu Apsaimniekosanas projekti Ltd, Grindeks RUS Ltd and Kalceks JSC. As of December 31, 2011, the Company’s major corporate shareholder was AB.LV Private Equity Fund 2010, with a stake of 11.38%.